文献速递治疗药物监测与药物基因组学抗菌药物管理

美国毕业后第二年感染病药学住院药师培训项目所在医疗体系β-内酰胺类治疗药物监测开展情况评价

Evaluation of β-lactam therapeutic drug monitoring among US health systems with postgraduate year 2 infectious diseases pharmacy residency programs.
PubMed 文献 · Am J Health Syst Pharm · 2022-01-01

该多中心横断面调查向美国126名PGY2感染病药学住院药师培训项目主任发放40项电子问卷,应答率31.7%(40/126)。仅8%(3/39)的应答机构开展β-内酰胺类TDM,各机构监测人群、靶目标及重复测浓度频率和时机差异大;最大障碍是缺乏快速周转的检测可及性。机构未来1年内实施意愿低,但5年内实施意愿显著更高(P < 0.001)。

要点

  • 美国受访医疗体系中β-内酰胺类TDM开展率仅8%(3/39)。
  • 已开展机构的监测人群、靶目标及复测频率和时机差异显著。
  • 快速周转检测不可及与缺乏美国特异性指南是主要实施障碍。

核心结论

  • 受访美国医疗体系中β-内酰胺类TDM开展不频繁。
  • 缺乏快速周转的血清浓度检测可及性与缺乏美国特异性指南似乎是实施β-内酰胺类TDM的显著障碍。
  • 已实施β-内酰胺类TDM的机构间监测方法存在显著差异。

研究设计与样本

  • 多中心、横断面、40项电子问卷调查研究。
  • 问卷发放给美国卫生系统药师协会药学住院药师目录中列出的全部PGY2感染病药学住院药师培训项目主任。
  • 问卷发放126名PGY2感染病项目主任,应答率31.7%(40/126)。
  • 主要结局为已建立β-内酰胺类TDM的机构百分比;次要结局包括评估TDM方法及识别实施障碍。

主要发现

  • 仅8%的应答者(3/39)开展β-内酰胺类TDM。
  • 各机构间患者人群、治疗靶目标以及重复β-内酰胺类浓度测定的频率和时机存在差异。
  • 实施的最大障碍是缺乏快速周转的检测可及性。
  • 机构未来1年内实施β-内酰胺类TDM的可能性低,但5年内实施意愿显著更高(P < 0.001)。

临床怎么用

  • 临床药学智能体在解读β-内酰胺类TDM结果时应关注机构间监测人群、靶目标及复测时机差异大的现实。
  • 推进β-内酰胺类TDM需优先解决快速周转的血清浓度检测可及性。
  • 可参考5年内实施意愿显著升高的趋势,提前规划本院β-内酰胺类TDM流程与能力建设。

局限性

  • 调查仅覆盖美国PGY2感染病药学住院药师培训项目主任所在医疗体系,应答率31.7%(40/126)。
  • 开展β-内酰胺类TDM的应答机构仅3家,相关监测方法描述有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: While some guidelines recognize the need for β-lactam therapeutic drug monitoring (TDM), there is still a paucity of data regarding the prevalence of and barriers to performing β-lactam TDM in the United States. We sought to estimate the prevalence of β-lactam TDM, describe monitoring practices, and identify actual and perceived barriers to implementation among health systems in the US. METHODS: A multicenter, cross-sectional, 40-item electronic survey was distributed to all postgraduate year 2 (PGY2) infectious diseases (ID) pharmacy residency program directors (RPDs) listed in the American Society of Health-System Pharmacists pharmacy residency directory. The primary outcome was the percentage of institutions with established β-lactam TDM. Secondary outcomes included assessing β-lactam TDM methods and identifying potential barriers to implementation. RESULTS: The survey was distributed to 126 PGY2 ID RPDs, with a response rate of 31.7% (40 of 126). Only 8% of respondents (3 of 39) performed β-lactam TDM. Patient populations, therapeutic targets, and frequency and timing of obtaining repeat β-lactam concentration measurements varied among institutions. The greatest barrier to implementation was lack of access to testing with a rapid turnaround time. Institutions were unlikely to implement β-lactam TDM within the next year but were significantly more inclined to do so within 5 years (P < 0.001). CONCLUSION: β-lactam TDM was infrequently performed at the surveyed US health systems. Lack of access to serum concentration testing with rapid turnaround and lack of US-specific guidelines appear to be considerable barriers to implementing β-lactam TDM. Among institutions that have implemented β-lactam TDM, there is considerable variation in monitoring approaches.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Chen C, Seabury RW, Steele JM, et al. Evaluation of β-lactam therapeutic drug monitoring among US health systems with postgraduate year 2 infectious diseases pharmacy residency programs. Am J Health Syst Pharm. 2022. PMID: 35439284. doi:10.1093/ajhp/zxac117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。